SystImmune Inc. clinical trials
A subsidiary of Sichuan Biokin Pharmaceutical Co., Ltd.
The registry lists 9 studies whose lead sponsor is SystImmune Inc.. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Registry sponsor names on this page
- SystImmune Inc.9 studies
Something wrong with this grouping? Tell us on the Sichuan Biokin Pharmaceutical Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All Sichuan Biokin Pharmaceutical Co., Ltd. studies →
- BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)RecruitingNCT07625644Phase 3
Sponsor listed in the registry: SystImmune Inc.
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsRecruitingNCT06293898Phase 1
Sponsor listed in the registry: SystImmune Inc.
- BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based TherapyRecruitingNCT07869836Phase 3
Sponsor listed in the registry: SystImmune Inc.
- SI-B036-ST-101 in Advanced/Metastatic Solid TumorsNot yet recruitingNCT07857616Phase 1
Sponsor listed in the registry: SystImmune Inc.
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsRecruitingNCT05983432Phase 1
Sponsor listed in the registry: SystImmune Inc.
- Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsRecruitingNCT07080242Phase 1
Sponsor listed in the registry: SystImmune Inc.
- Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1TerminatedNCT06714591Phase 1
Sponsor listed in the registry: SystImmune Inc.
- Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsTerminatedNCT06714617Phase 1
Sponsor listed in the registry: SystImmune Inc.
- Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid TumorsActive, not recruitingNCT07021066Phase 1
Sponsor listed in the registry: SystImmune Inc.